Effects of Periodic Fasting on Fatty Liver Index—A Prospective Observational Study

This prospective observational trial investigated effects and safety of periodic fasting in subjects with and without type 2 diabetes mellitus (T2DM). The primary end point was set as the change of fatty liver index (FLI) as a surrogate parameter of non-alcoholic fatty liver disease (NAFLD). Six-hundred and ninety-seven subjects (38 with T2DM) were enrolled. A baseline FLI ≥ 60 (the threshold for fatty liver) was found in 264 subjects (37.9%). The mean duration of fasting was 8.5 ± 4.0 days (range 6–38). FLI decreased significantly (−14.02 ± 11.67; p < 0.0001), with a larger effect in individuals with T2DM (−19.15 ± 11.0; p < 0.0001; p = 0.002 compared to non-diabetic subjects). Body mass index (BMI) decreased by −1.51 ± 0.82 kg/m2, and 49.9% of the subjects lost ≥5% body weight. After fasting, nearly half of the 264 subjects with FLI ≥ 60 (highest risk category) shifted to a lower category. The improvement of FLI correlated with the number of fasting days (r = −0.20, p < 0.0001) and with the magnitude of BMI reduction (r = 0.14, p = 0.0001). Periodic fasting with concomitant weight reduction leads to significant rapid improvement of FLI in subjects with and without T2DM.

[1]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[2]  Roy Taylor,et al.  Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial , 2017, The Lancet.

[3]  P. Kerndt,et al.  Fasting: the history, pathophysiology and complications. , 1982, The Western journal of medicine.

[4]  A. Michalsen,et al.  Effects of A One-week Fasting Therapy in Patients with Type-2 Diabetes Mellitus and Metabolic Syndrome – A Randomized Controlled Explorative Study , 2017, Experimental and Clinical Endocrinology & Diabetes.

[5]  S. Moebus,et al.  Incorporation of fasting therapy in an integrative medicine ward: evaluation of outcome, safety, and effects on lifestyle adherence in a large prospective cohort study. , 2005, Journal of alternative and complementary medicine.

[6]  S. Burgess,et al.  Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. , 2011, The American journal of clinical nutrition.

[7]  A. Stein,et al.  Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review. , 2018, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[8]  A. Michalsen,et al.  Fasting Therapy for Treating and Preventing Disease - Current State of Evidence , 2013, Complementary Medicine Research.

[9]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[10]  J. George,et al.  The role of diet and nutritional intervention for the management of patients with NAFLD. , 2014, Clinics in liver disease.

[11]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[12]  Benjamin S. Aribisala,et al.  Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery. , 2018, Cell metabolism.

[13]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[14]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[15]  Anna Castiglione,et al.  The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population , 2006, BMC gastroenterology.

[16]  Feng Li,et al.  Weight reduction for non-alcoholic fatty liver disease. , 2011, The Cochrane database of systematic reviews.

[17]  A. Roverato,et al.  Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta‐analysis , 2016, Journal of gastroenterology and hepatology.

[18]  R. Schwenk,et al.  Caloric restriction and intermittent fasting alter hepatic lipid droplet proteome and diacylglycerol species and prevent diabetes in NZO mice. , 2015, Biochimica et biophysica acta.

[19]  A. Suzuki,et al.  Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[20]  A. Michalsen,et al.  Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects , 2019, PloS one.

[21]  A. Moschetta,et al.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 , 2015, Nature Reviews Drug Discovery.

[22]  T. Elhadd,et al.  Differential effects of gender and patient background diversity on the changes in metabolic and biophysical profiles in people with type-2 diabetes from different ethnicities who fast during Ramadan (H1439); a prospective study from Qatar. , 2019, Diabetes research and clinical practice.

[23]  V. Wong,et al.  Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. , 2018, Journal of hepatology.

[24]  Magnolia Cardona-Morrell,et al.  Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis , 2010, BMC public health.

[25]  S. Shin,et al.  Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. , 2014, New England Journal of Medicine.

[26]  R. Tayyem,et al.  Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors. , 2018, Diabetes & metabolic syndrome.

[27]  Y. Rotman,et al.  Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease , 2016, Gut.

[28]  A. Michalsen,et al.  Fasting Therapy - an Expert Panel Update of the 2002 Consensus Guidelines , 2013, Complementary Medicine Research.

[29]  P. Puchalska,et al.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.

[30]  K. Khunti,et al.  Diabetes Prevention in the Real World: Effectiveness of Pragmatic Lifestyle Interventions for the Prevention of Type 2 Diabetes and of the Impact of Adherence to Guideline Recommendations , 2014, Diabetes Care.

[31]  C. Day,et al.  Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance , 2016, British Medical Journal.

[32]  L. Adams,et al.  International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease , 2022 .

[33]  Xuchen Zhang,et al.  Non-alcoholic fatty liver disease: An expanded review , 2017, World journal of hepatology.

[34]  K. Faber,et al.  Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort , 2017, PloS one.

[35]  George F Cahill,et al.  Fuel metabolism in starvation. , 2006, Annual review of nutrition.

[36]  Amalia Gastaldelli,et al.  Comparison of Liver Fat Indices for the Diagnosis of Hepatic Steatosis and Insulin Resistance , 2014, PloS one.

[37]  Benjamin S. Aribisala,et al.  Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol , 2011, Diabetologia.

[38]  F. Schick,et al.  The impact of liver fat vs visceral fat in determining categories of prediabetes , 2010, Diabetologia.

[39]  S. O. Lima,et al.  Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index , 2015, Gastroenterology research.

[40]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[41]  G. Shulman Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. , 2014, The New England journal of medicine.

[42]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[43]  G. Marchesini,et al.  AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[44]  M. Laakso,et al.  Ketone body production is differentially altered in steatosis and non‐alcoholic steatohepatitis in obese humans , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[45]  J. Krakauer,et al.  The association between a body shape index and cardiovascular risk in overweight and obese children and adolescents , 2018, PloS one.